AzurRx clips its IPO price, but manages to get the job done
These days, completing a biotech IPO often means settling for less. And AzurRx BioPharma is lowering its sights to a micro offering worth about $5 million.
The Brooklyn, NY-based biotech shrugged off its earlier range of $6 to $8 a share, settling for $5.50 on a little less than a million shares. The biotech plans to use the cash to back its work on non-systemic GI drugs.
Biotech IPOs have had a rocky experience this year, the natural result of the end of the gangbuster reception that greeted these offerings for the previous three years. But, one way or another, several are getting done.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.